{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[],"indication":"castration sensitive oligometastatic prostate cancer","name":"START-MET","nct_id":"NCT05209243","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=start-met-nct05209243. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"START-MET","arms":[{"description":"STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment","label":"Interventional arm","type":"EXPERIMENTAL"},{"description":"STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment","label":"Control arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-01","type":"ESTIMATED"},"conditions":["Prostate Cancer","Stereotactic Body Radiation Therapy"],"enrollment":{"count":266,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"SBRT","otherNames":[],"type":"RADIATION"},{"name":"STANDARD OF CARE","otherNames":[],"type":"RADIATION"}],"last_update":"2023-05-19","lead_sponsor":"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic","official_title":"Phase III Study of Stereotactic Body Radiation Therapy (SBRT) Plus Standard of Care in Castration Sensitive Oligometastatic Prostate Cancer Patients.","overall_status":"RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2025-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Radiological progression-free survival (rPFS)","timeFrame":"An average of two years"}],"references":[],"start_date":{"date":"2023-01-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC","url":"https://clinicaltrials.gov/study/NCT05209243"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/start-met-nct05209243"}